N. A. Lushnikova

N. A. Lushnikova

Auto-generated profile, based on publicly available information

N. A. Lushnikova

Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2021 in Siberian journal of oncology
Verified
Journal Article
Open access
PDF file
AMAnna Medvedeva
Anna Medvedeva
VCVladimir Chernov
Vladimir Chernov
EUE. A. Usynin
E. A. Usynin
RZRoman Zelchan
Roman Zelchan
OBOlga Bragina
Olga Bragina
NLN. A. Lushnikova
N. A. Lushnikova
Purpose of the study: to present current data regarding challenges in treatment of castration-resistant prostate cancer (CRPC) and the relationship between CRPC and the expression of prostate-specific membrane antigen (psma).Material and Methods. The search for relevant sources was carried out in the Pubmed, elibrary, Medline databases. The review included 43 publications, most of which were published over the past 5 years.Results. Currently, prostate cancer (PC) is one of the most common cancers in men. Moreover, over time, most patients develop resistance to therapy, which significantly worsens the prognosis of the disease. Psma is one of the molecular markers of prostate cancer; a number of studies have demonstrated a direct correlation between the level of psma expression and the tumor grade, stage and aggressiveness. Numerous studies indicate that psma represents an excellent target for radionuclide therapy of prostate cancer. 68Ga or 18F-psma Pet/Ct is the most common method for diagnosing PC. It should be noted that modern trends in the development of nuclear medicine are closely related to theranostics; therefore, the creation of highly specific theranostic pairs for diagnosis and subsequent therapy of malignant tumors is of great significance. The data obtained indicate that 177lu demonstrates the most optimal radiation and physical characteristics for therapeutic radionuclides, while psma-617 is one of the most studied ligands for radionuclide therapy.Conclusion. Currently, there are several studies covering radionuclide therapy with various psmacompounds labeled with 177lu. Radionuclide therapy with 177lu-psma has been shown to be recommended for patients with metastatic CRPC, who have no benefits from alternative therapies or have contraindications to them.

30 June 2019 in Cancer Urology
Verified
Journal Article
Open access
PDF file
ZYZ. A. Yurmazov
Z. A. Yurmazov
НЛНадежда Андреевна Лушникова
Надежда Андреевна Лушникова
LSLuidmila Spirina
Luidmila Spirina
EUE. A. Usynin
E. A. Usynin
ESE. M. Slonimskaya
E. M. Slonimskaya
ABA. V. Bogoutdinova
A. V. Bogoutdinova
The study objective is to evaluate the effectiveness of preoperative targeted therapy, spectrum and rate of adverse events, as well as quality of life in patients with bone metastases of renal cell carcinoma.Materials and methods. The study was conducted at the Research Institute of Oncology, Tomsk Medical Research Center between 2014 and 2018. The study included 34 patients with bone metastases of renal cell carcinoma who received preoperative targeted therapy with pazopanib for 8 weeks. All patients underwent surgical treatment of both the primary tumor and bone metastases.Results and conclusion. It was shown that preoperative targeted therapy is characterized by a high rate of clinical response and satisfactory tolerability. In some cases, preoperative targeted therapy improves the conditions for surgical treatment of metastatic bone lesions, decreases intraoperative blood loss, decreases the volume and duration of surgical intervention, which, in turn, allows to preserve bigger range of motion in the affected bone segment and improve patients’ quality of life.

7 May 2022 in Cancer Urology
Verified
Journal Article
Open access
PDF file
ZYZ. A. Yurmazov
Z. A. Yurmazov
EUE. A. Usynin
E. A. Usynin
AMAnna Medvedeva
Anna Medvedeva
APA. A. Polyakov
A. A. Polyakov
NLN. A. Lushnikova
N. A. Lushnikova
LSLuidmila Spirina
Luidmila Spirina
Background. Prostate cancer is one of the actual problems of modern oncology. The incidence of prostate cancer is steadily increasing despite of popularization of screening and early diagnostics. It is worth to highlight separately the castration-resistant prostate cancer which develops on the average 2 years after surgical or medicinal castration. For the patients with metastatic castration-resistant prostate cancer (mCRPC) the main purpose of treatment is increasing of overall survival while maintaining the quality of life. Currently there are several treatment options for mCRPC: chemotherapy, inhibitors of androgen receptor pathway,systemic alfa-radiotherapy, PARP-inhibitorsfor homologousrecombination DNA repair deficiency. Using of several sequential lines of mCRPC therapy leads to maintaining the patients’ quality of life and increasing its duration. Systemic alfa-radiotherapy is using since 2013 – the first is radium-223 which was approved by Food and Drug Administration according the results of the phase III trial ALSYMPCA. In Russian Federation radium-223 was approved in 2016.Objective: to evaluate the efficiency and safety oftherapy with radium-223 as well as pain response at patients with mCRPC.Materials and methods. 67 patients were included in this analysis who received radium-223 therapy at Scientific Research Institute of Tomsk National Research Medical Center of Russian Academy of Sciences and Tomsk Regional Oncology Dispensary.Results and conclusion. Radium-223 has demonstrated its efficiency for mCRPC patients with good safety profile and positive pain response and maintaining the QoL.

14 August 2022 in Cancer Urology
Verified
Journal Article
Open access
PDF file
ZYZ. A. Yurmazov
Z. A. Yurmazov
NLN. A. Lushnikova
N. A. Lushnikova
EUE. A. Usynin
E. A. Usynin
NBN. V. Bezgodova
N. V. Bezgodova
EGE. G. Grigoriev
E. G. Grigoriev
Ewing’s sarcoma is a highly aggressive malignant tumor that often affects the bones. Genitourinary organs are an exceedingly rare location of the Ewing’s sarcoma. There are still no widely accepted treatment protocols for such patients. We report a rare case of Ewing’s sarcoma of the ureter in a 68-year-old man who was admitted to the Cancer Research Institute, Tomsk National Research Medical Center. He was suspected of having a bladder tumor. After completing his treatment course which included surgery and adjuvant chemotherapy, the patient demonstrated no signs of local recurrence or metastasis for a long time.